CD(Suzhou)Biopharma

Connect Biopharma is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research. The company leverages its expertise in biology and high-throughput screening to identify and advance small molecules and antibodies that modulate critical immune pathways. Its lead program, rademikibart (CBP-201), is a monoclonal antibody targeting IL-4Rα currently in Phase 3 trials for atopic dermatitis. Additionally, the company is developing icanbelimod (CBP-307), an S1P1 receptor modulator for ulcerative colitis, and other early-stage assets targeting GPR15 and IL-33.